Insider · CIK 0001738701
Chirag K. Patel
ceopresidentofficerdirector
Files at AMRX (Amneal Pharmaceuticals, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | AMRX Amneal Pharmaceuticals, Inc. | AGrant or award Performance-Based Restricted Stock Unitsderivative | +544,663 | $0.00 | $0 | 544,663 | Mar 27, 2026 |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | MOption exercise Class A Common Stock | +59,931 | - | - | 917,911 | Mar 5, 2026 |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | FTax withholding Class A Common Stock | -15,616 | $13.31 | $208k | 902,295 | Mar 5, 2026 |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | MOption exercise Class A Common Stock | +733,944 | - | - | 1,636,239 | Mar 5, 2026 |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | FTax withholding Class A Common Stock | -297,537 | $13.31 | $4.0M | 1,338,702 | Mar 5, 2026 |
| Mar 4, 2026 | AMRX Amneal Pharmaceuticals, Inc. | MOption exercise Class A Common Stock | +92,593 | - | - | 1,431,295 | Mar 5, 2026 |
| Mar 4, 2026 | AMRX Amneal Pharmaceuticals, Inc. | FTax withholding Class A Common Stock | -37,825 | $13.30 | $503k | 1,393,470 | Mar 5, 2026 |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -59,931 | $0.00 | $0 | 179,795 | Mar 5, 2026 |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | MOption exercise Performance-Based Restricted Stock Unitsderivative | -733,944 | $0.00 | $0 | 0 | Mar 5, 2026 |
| Mar 4, 2026 | AMRX Amneal Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -92,593 | $0.00 | $0 | 185,185 | Mar 5, 2026 |
| Mar 2, 2026 | AMRX Amneal Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +190,632 | $0.00 | $0 | 190,632 | Mar 3, 2026 |
| Mar 2, 2026 | AMRX Amneal Pharmaceuticals, Inc. | AGrant or award Performance-Based Restricted Stock Unitsderivative | +354,031 | $0.00 | $0 | 354,031 | Mar 3, 2026 |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | MOption exercise Class A Common Stock | +579,710 | - | - | 1,092,276 | Mar 5, 2025 |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | FTax withholding Class A Common Stock | -279,527 | $8.76 | $2.4M | 812,749 | Mar 5, 2025 |
| Mar 4, 2025 | AMRX Amneal Pharmaceuticals, Inc. | MOption exercise Class A Common Stock | +92,592 | - | - | 905,341 | Mar 5, 2025 |
| Mar 4, 2025 | AMRX Amneal Pharmaceuticals, Inc. | FTax withholding Class A Common Stock | -47,361 | $8.84 | $419k | 857,980 | Mar 5, 2025 |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | MOption exercise Performance-Based Restricted Stock Unitsderivative | -579,710 | $0.00 | $0 | 0 | Mar 5, 2025 |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | AGrant or award Performance-Based Restricted Stock Unitsderivative | +890,410 | $0.00 | $0 | 890,410 | Mar 5, 2025 |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +239,726 | $0.00 | $0 | 239,726 | Mar 5, 2025 |
| Mar 4, 2025 | AMRX Amneal Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -92,592 | $0.00 | $0 | 277,778 | Mar 5, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.